Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666770 · ClinicalTrials.gov registry record · Phase 3
A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
A Phase 3 study of Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
- 5
- Study locations
NCT00666770: Completed Phase 3 study of Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00666770 is a Phase 3 study of Transient Insomnia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 309 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666770, a Phase 3 study of Transient Insomnia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep in subjects with transient insomnia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gabapentin
Study Locations (5)
California
- Pfizer Investigational Site - Glendale
- Pfizer Investigational Site - San Diego
Kansas
- Pfizer Investigational Site - Overland Park
- Pfizer Investigational Site - Overland Park
New York
- Pfizer Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2004-10 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
What the finished NCT00666770 record still lists
NCT00666770 is an interventional study that assigns participants to a tested intervention. The registered 309 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Transient Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00666770 lists 5 locations in 3 states (California, Kansas, New York).
Frequently Asked Questions
What is clinical trial NCT00666770 about?
NCT00666770 is a clinical study titled "A Polysomnographic Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance". The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep in subjects with transient insomnia.
What is the current status of trial NCT00666770?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2004-10. Estimated completion is 2004-11.
What conditions does trial NCT00666770 study?
This clinical trial studies the following conditions: Transient Insomnia.
What interventions are being tested in trial NCT00666770?
The interventions under investigation include: Placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00666770?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666770 being conducted?
This trial has 5 study locations across California, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transient Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666770's enrollment target sits among peer trials
309 1109th of 2000 higher than 889 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03011684 · 309 participants · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
- NCT06915233 · 309 participants · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia